Abstract:Background: Targeting the CD47/SIRPα signaling pathway represents a novel approach to enhance anti-tumor immunity. However, the crystal structure of the CD47/SIRPα has not been fully studied. This study aims to analyze the structure interface of the complex of CD47 and IMM01, a novel recombinant SIRPα-Fc fusion protein. Methods: IMM01-Fab/CD47 complex was crystalized, and diffraction images were collected. The complex structure was determined by molecular replacement using the program PHASER with the CD47-SIRPαv2 structure (PDB code 2JJT) as a search model. The model was manually built using the COOT program and refined using TLS parameters in REFMAC from the CCP4 program suite. Results: Crystallization and structure determination analysis of the interface of IMM01/CD47 structure demonstrated CD47 surface buried by IMM01. Comparison with the literature structure (PDB ID 2JJT) showed that the interactions of IMM01/CD47 structure are the same. All the hydrogen bonds that appear in the literature structure are also present in the IMM01/CD47 structure. These common hydrogen bonds are stable under different crystal packing styles, suggesting that these hydrogen bonds are important for protein binding. In the structure of human CD47 in complex with human SIRPα, except SER66, the amino acids that form hydrogen bonds are all conserved. Furthermore, comparing with the structure of PDB ID 2JJT, the salt bridge interaction from IMM01/CD47 structure are very similar, except the salt bridge bond between LYS53 in IMM01 and GLU106 in CD47, which only occurs between the B and D chains. However, as the side chain conformation of LYS53 in chain A is slightly different, the salt bridge bond is absent between the A and C chains. At this site between chain A and chain C, there are a salt bridge bond between LYS53 (A) and GLU104 (C) and a salt bridge bond between HIS56 (A) and GLU106 (C) instead. According to the sequence alignment results of SIRPα, SIRPβ and SIRPγ in the literature of PDB ID 2JJT, except ASP100, the amino acids that form common salt bridge bonds are all conserved. Conclusion: Our data demonstrated crystal structure of the IMM01/CD47 complex and provides a structural basis for the structural binding interface and future clinical applications.

Single-molecule-force spectroscopy study of the mechanism of interactions between TSP-1 and CD47

Studying the Mechanism of CD47-SIRPα Interactions on Red Blood Cells by Single Molecule Force Spectroscopy.

A MD Simulation Prediction for Regulation of N-Terminal Modification on Binding of CD47 to CD172a in a Force-Dependent Manner

Structural mechanism of TCR-pMHC catch bond revealed by molecular dynamics, mutagenesis, and single-molecule kinetics analyses (IRM10P.752)

Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations

Thrombospondin-1/CD47 signaling modulates transmembrane cation conductance, survival, and deformability of human red blood cells

Single-molecule Force Spectroscopy Study of Interaction Between Transforming Growth Factor Beta1 and Its Receptor in Living Cells.

Membrane-Mediated Cooperative Interactions of CD47 and SIRP<i></i>

Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1

Super-resolution microscopy unveils the nanoscale organization and self-limiting clustering of CD47 in human erythrocytes

Structural–functional diversity of CD47 proteoforms

CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes

Investigation of the Interaction Between Split Aptamer and Vascular Endothelial Growth Factor 165 Using Single Molecule Force Spectroscopy.

Design single-stranded DNA aptamer of cluster of differentiation 47 protein by stochastic tunnelling-basin hopping-discrete molecular dynamics method

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

Targeting CD47: the Achievements and Concerns of Current Studies on Cancer Immunotherapy

Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent

Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models

Microvascular Dysfunction Following Multiwalled Carbon Nanotube Exposure Is Mediated by Thrombospondin-1 Receptor CD47

Biomimetic Design of Peptide Inhibitor to Block CD47/SIRP Interactions

Detection of CD28/CD86 Co-Stimulatory Molecules and Surface Properties of T and Dendritic Cells: an AFM Study.